| |
|
|
|
|
|
|
|||
|
Blood, 1 August 2005, Vol. 106, No. 3, pp. 1063-1066. Prepublished online as a Blood First Edition Paper on April 19, 2005; DOI 10.1182/blood-2004-08-3225.
NEOPLASIA
Essential role for the p110
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
C. A. Durand, K. Hartvigsen, L. Fogelstrand, S. Kim, S. Iritani, B. Vanhaesebroeck, J. L. Witztum, K. D. Puri, and M. R. Gold Phosphoinositide 3-Kinase p110{delta} Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses J. Immunol., November 1, 2009; 183(9): 5673 - 5684. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, and Y. Ge RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia Blood, September 24, 2009; 114(13): 2744 - 2752. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamburini, A. S. Green, V. Bardet, N. Chapuis, S. Park, L. Willems, M. Uzunov, N. Ifrah, F. Dreyfus, C. Lacombe, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia Blood, August 20, 2009; 114(8): 1618 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Hercus, D. Thomas, M. A. Guthridge, P. G. Ekert, J. King-Scott, M. W. Parker, and A. F. Lopez The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease Blood, August 13, 2009; 114(7): 1289 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Geest, F. J. Zwartkruis, E. Vellenga, P. J. Coffer, and M. Buitenhuis Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells Haematologica, July 1, 2009; 94(7): 901 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saudemont, F. Garcon, H. Yadi, M. Roche-Molina, N. Kim, A. Segonds-Pichon, A. Martin-Fontecha, K. Okkenhaug, and F. Colucci p110{gamma} and p110{delta} isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease PNAS, April 7, 2009; 106(14): 5795 - 5800. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Billottet, L. Banerjee, B. Vanhaesebroeck, and A. Khwaja Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation Cancer Res., February 1, 2009; 69(3): 1027 - 1036. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. T. Ihle and G. Powis Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy Mol. Cancer Ther., January 1, 2009; 8(1): 1 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Zebedin, O. Simma, C. Schuster, E. M. Putz, S. Fajmann, W. Warsch, E. Eckelhart, D. Stoiber, E. Weisz, J. A. Schmid, et al. Leukemic challenge unmasks a requirement for PI3K{delta} in NK cell-mediated tumor surveillance Blood, December 1, 2008; 112(12): 4655 - 4664. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Webb, A. Johnson, M. Fortunato, A. Platt, T. Crabbe, M. I. Christie, G. F. Watt, S. G. Ward, and L. A. Jopling Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists J. Leukoc. Biol., October 1, 2008; 84(4): 1202 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Grech, M. Blazquez-Domingo, A. Kolbus, W. J. Bakker, E. W. Mullner, H. Beug, and M. von Lindern Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation Blood, October 1, 2008; 112(7): 2750 - 2760. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Boller, A. Schramm, K. T. Doepfner, T. Shalaby, A. O. von Bueren, A. Eggert, M. A. Grotzer, and A. Arcaro Targeting the Phosphoinositide 3-Kinase Isoform p110{delta} Impairs Growth and Survival in Neuroblastoma Cells Clin. Cancer Res., February 15, 2008; 14(4): 1172 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Recher A critical role for Lyn in acute myeloid leukemia Blood, February 15, 2008; 111(4): 2269 - 2279. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamburini, N. Chapuis, V. Bardet, S. Park, P. Sujobert, L. Willems, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways Blood, January 1, 2008; 111(1): 379 - 382. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Buitenhuis, L. P. Verhagen, H. W. M. van Deutekom, A. Castor, S. Verploegen, L. Koenderman, S.-E. W. Jacobsen, and P. J. Coffer Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis Blood, January 1, 2008; 111(1): 112 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Schoenwaelder, A. Ono, S. Sturgeon, S. M. Chan, P. Mangin, M. J. Maxwell, S. Turnbull, M. Mulchandani, K. Anderson, G. Kauffenstein, et al. Identification of a Unique Co-operative Phosphoinositide 3-Kinase Signaling Mechanism Regulating Integrin {alpha}IIbbeta3 Adhesive Function in Platelets J. Biol. Chem., September 28, 2007; 282(39): 28648 - 28658. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamburini, C. Elie, V. Bardet, N. Chapuis, S. Park, P. Broet, P. Cornillet-Lefebvre, B. Lioure, V. Ugo, O. Blanchet, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients Blood, August 1, 2007; 110(3): 1025 - 1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Follo, S. Mongiorgi, C. Bosi, A. Cappellini, C. Finelli, F. Chiarini, V. Papa, M. Libra, G. Martinelli, L. Cocco, et al. The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation Cancer Res., May 1, 2007; 67(9): 4287 - 4294. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Deane, M. G. Kharas, J. S. Oak, L. N. Stiles, J. Luo, T. I. Moore, H. Ji, C. Rommel, L. C. Cantley, T. E. Lane, et al. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling Blood, April 1, 2007; 109(7): 2894 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamburini, N. Chapuis, V. Bardet, S. Park, F. Verdier, F. Dreyfus, C. Lacombe, and D. Bouscary Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1904 - 1904. [Abstract] [PDF] |
||||
![]() |
Z. Zeng, I. J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, D. Harris, O. Frolova, N. Hail Jr., W. Chen, S. M. Kornblau, et al. Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia. Cancer Res., April 1, 2006; 66(7): 3737 - 3746. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kang, A. Denley, B. Vanhaesebroeck, and P. K. Vogt Oncogenic transformation induced by the p110beta, -{gamma}, and -{delta} isoforms of class I phosphoinositide 3-kinase PNAS, January 31, 2006; 103(5): 1289 - 1294. [Abstract] [Full Text] [PDF] |
||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||